Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Amelia de la Rubia Nieto"'
Autor:
Belén Cabezuelo Escribano, Vicente Arocas Casañ, Beatriz Garrido-Corro, Pablo de la Cruz Murie, Mª José Blázquez Álvarez, M.ª Amelia de la Rubia Nieto
Publikováno v:
Farmacia Hospitalaria, Vol 41, Iss 3, Pp 371-381 (2017)
Objetive: To describe off-label and unlicensed drugs in clinical practice in a Neonatal Intensive Care Unit (NICU).Method: The design of the study was a descriptive and retrospective three months research in a NICU of a Spanish University Hospital. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::28d6cdc128417def5091e85cc022bf68
https://doaj.org/article/a3a0337d94294e859a0e51f3b2f7e9f3
https://doaj.org/article/a3a0337d94294e859a0e51f3b2f7e9f3
Autor:
Mª. Ángeles Fernández de Palencia Espinosa, Alberto Espuny Miró, Andrés Sánchez Salinas, Amelia de la Rubia Nieto, Ma Sacramento Díaz Carrasco
Publikováno v:
Journal of Oncology Pharmacy Practice. 23:443-453
Background Frequently, haematological patients undergo highly complex and intensive treatment protocols, so a high risk of drug–drug interactions could be expected. Objectives To determine prevalence of clinically relevant drug–drug interactions,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75e2b587ac0f74f1151984a291c20485
https://doi.org/10.1177/1078155216664201
https://doi.org/10.1177/1078155216664201
Autor:
Vicente Arocas Casañ, Jaime Mateo Carmona, Olga García Molina, Mº Ángeles Fernández de Palencia Espinosa, Mª José Blázquez Álvarez Espinosa, Mª Amelia de la Rubia Nieto, Jesús del Río García
Publikováno v:
Farmacia Hospitalaria, Vol 40, Iss 2, Pp 63-78 (2016)
Objectives: To develop a procedure for management of off-label medications, and to analyze the treatments, indications, and hospital units which will request them more frequently, as well as which variables will have an impact on the authorization de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::3443d6b6d107018c47e48aa5c483cb18
http://www.aulamedica.es/fh/pdf/9268.pdf
http://www.aulamedica.es/fh/pdf/9268.pdf
Autor:
Sergio Vicente-Sánchez, Raquel Olmos-Jiménez, Cristina Ramírez-Roig, María José García-Sánchez, Manuel Valderrey-Pulido, Amelia de la Rubia-Nieto
Publikováno v:
Farmacia Hospitalaria, Vol 42, Iss 4, Pp 147-151 (2018)
Analyze the frequency of therapeutic noncompliance in patients who suffer early readmissions, and identify the factors associated with it.Observational, descriptive study of three months duration (March - May 2014). All patients older than 65 years w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e38b7843e1113d05863bab7b5d4bc388
https://pubmed.ncbi.nlm.nih.gov/29959838
https://pubmed.ncbi.nlm.nih.gov/29959838
Autor:
José Luis Alonso Romero, Alberto Espuny Miró, Ma Sacramento Díaz Carrasco, Amelia de la Rubia Nieto, Mª. Ángeles Fernández de Palencia Espinosa
Publikováno v:
International journal of clinical pharmacy. 37(6)
Background Oncological patients are at high risk for drug–drug interactions (DDIs), which may contribute to therapeutic failure or lead to serious adverse events. Objective To determine the prevalence of potential DDIs in medication lists, to descr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc13ba78a3319a07b2954e4467ff3752
https://pubmed.ncbi.nlm.nih.gov/26391788
https://pubmed.ncbi.nlm.nih.gov/26391788
Autor:
Guadalupe Ruíz Merino, M. Amelia De la Rubia Nieto, Alberto Espuny Miró, M. Sacramento Díaz Carrasco, José Luis Fuster Soler, M. Angeles Fernández de Palencia Espinosa
Publikováno v:
International journal of clinical pharmacy. 36(6)
Background Onco-hematological patients are particularly susceptible to drug–drug interactions (DDIs) because they often undergo multiple combined treatments. Some studies have analyzed the frequency of DDIs in adult patients with cancer; however, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0d8f5a9b1b26e1c3c12bfaa2513b8f0
https://pubmed.ncbi.nlm.nih.gov/25204258
https://pubmed.ncbi.nlm.nih.gov/25204258
Autor:
P De La Cruz Murie, J Mateo Carmona, J Velasco Costa, R Olmos Jimenez, C Ramirez Roig, MC Muñoz Contreras, Mª Amelia de la Rubia Nieto, M Almanchel Rivadeneyra
Publikováno v:
European Journal of Hospital Pharmacy. 21:A132.1-A132
Background This syndrome is due to a birth defect in cholesterol synthesis and caused by mutations in the DHCR7 gene, which lead to a deficiency of the enzyme that converts 7-dehydrocholesterol to cholesterol. Management is symptomatic and most patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31363ffb3046fea6fd8c50647ccc13f6
https://doi.org/10.1136/ejhpharm-2013-000436.325
https://doi.org/10.1136/ejhpharm-2013-000436.325